348
Participants
Start Date
September 10, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Pirfenidone
"Initial dose titration:~First week (days 1-7): 1 capsule (267 mg), 3 times daily (801 mg/day)~Second week (days 8-14): 2 capsules (534 mg), 3 times daily (1602 mg/day)~Maintenance dose:~Third week and thereafter (days 15-90): 3 capsules (801 mg), 3 times daily (2403 mg/day)"
Placebo for pirfenidone
"First week (days 1-7): 1 capsule, 3 times daily~Second week (days 8-14): 2 capsules, 3 times daily~Third week and thereafter (days 15-90): 3 capsules, 3 times daily"
Upadacitinib
1 capsule (15 mg), once daily for 90 days
Placebo for upadacitinib
1 capsule, once daily for 90 days
NOT_YET_RECRUITING
Joint Clinical Research Centre (JCRC), Kampala
NOT_YET_RECRUITING
University Teaching Hospital, Lusaka
RECRUITING
Laura Rodriguez Research Institute, San Diego
NOT_YET_RECRUITING
Ini-Fiocruz, Rio de Janeiro
RECRUITING
Institut de Recherches Cliniques de Montréal (IRCM), Montreal
NOT_YET_RECRUITING
Centre de Recherche du CHUS (CRCHUS), Sherbrooke
NOT_YET_RECRUITING
INMI Lazzaro Spallanzani IRCCS, Roma
NOT_YET_RECRUITING
Sapienza Università di Roma, Roma
Douglas D. Fraser
OTHER